Redeye states that Ngenics preliminary sales figures are impressive, with total sales of SEK14.
Paper prices to decline further, but too late for some customers '23e-'25e revenues down 1-2%, EBIT ...
Maven Wireless kommunicerade under veckan att bolagets produkter har erhållit godkännande för att et...
Redeye is encouraged to learn that the first healthy volunteer has been dosed in the company’s phase...
Cantargia has presented new data from the Phase I/IIa CANFOUR trial at the American Association for ...
Redeye returns with a view on Tesofensine following the positive opinion of the drug as an obesity t...
Redeye initiates coverage of TECO 2030, a Norwegian fuel cell manufacturer targeting hard-to-decarbo...
Clients still overstocked, but demand is holding up 3% q-o-q order booking decline '23e-'25e EBIT do...
Redeye updates its estimates and valuation on the back of the Q4 2022 report and recent right issue.
Q1'23e should be solid... .. but few strategic updates likely after CMD in March Therefore, the repo...
Redeye shares its preview of Sedana Medical’s Q1 2023e results, due on February 16.
Redeye is encouraged by the first report from Annexin’s imaging study (n=16), which indicates site-s...
Starkt Q1 underbygger förväntningar på 2023 Eagle Filters redovisar intäkter för Q1 om EUR 1,5 m, mo...
Redeye comments on today’s press release, underlining the company’s critical financial situation.
Redeye’s comments on Cellavisions profit warning that was issued yesterday.
Redeye provides a research update following Hoylu’s Q1 2023 report.
On the back of the framework agreement with the Swedish Security Council (TRR) for Bonzun’s digital ...
Cantargia yesterday published important results in pancreatic cancer at the AARC annual meeting.
Q1'23 on Thursday, 20 April We expect sales of SEK 59m, +9% y-o-y Trading at 17x EV/EBITDA on '24e ...
Another bad debt provision likely to hurt Q1e, easing in Q2e We cut '23e sales by 8% and '24-'25e by...
